Monthly Investor Update March 2022





Return	NTA cps Feb 2022	Month (%)	Quarter (%)	FYTD (%)	1 Year (% pa)	2 Years (% pa)	Since Inception <sup>3</sup> (% pa)
Precision Opportunities Fund Ltd <sup>1</sup>	40.26	6.1	1.6	21.0	38.4	51.3	18.7
Benchmark <sup>2</sup>	-	0.2	0.5	1.7	2.2	2.2	3.1
Outperformance	_	5.9	1.1	19.3	36.2	49.2	15.6

#### Overview

The fund returned 6.1% for the month to reach an NTA of 40.26c. Global indices all performed well with Nasdaq up 4.2% and the S&P 3.6% and this flowed through into the local indices with Small Ord All up 5.3% and All Ords up 6.9%. Commodity prices had a volatile month, especially Nickel which hit a record high of US\$100,000/t on a 'short squeeze' and subsequent LME suspension of trading. We took the opportunity to lock in some profits in Mincor Resources which hit a multi year high of \$2.40/sh and a ~4x uplift on our entry price. We bought some Nickel Mines Ltd ('NIC') as it was sold down on fears one of its major shareholders, Tsingshan would be a seller due to this short squeeze. Gold spiked to US\$2,050/oz on a safe haven/inflation hedge and spent the month above US\$1,900/oz. We took the opportunity to lock in some profits in Capricorn Metals which has been a stellar performer, up >150% in the past year and 6x on our average entry price. Lithium prices continued their record run with some spot spodumene sales >US\$5,000/t and Lithium Carbonate prices of >US\$50,000/t. Lithium equities responded with many hitting multi year highs and retracing the lost ground after the volatility of the prior two months.

Our Top three stocks all returned greater than 1% attribution

Our top performer was Firefinch Ltd ('FFX') which added 60% for the month after it announced all the conditions for the transfer of the Goulamina Exploitation Licence had been met. This triggers the US\$170m funding package provided by Ganfeng to the JV and allows for the ordering of long lead items in April. The demerger of Leo Lithium Ltd ('LLL') from FFX will now proceed and likely to occur in the 2<sup>nd</sup> Q CY'22. Only FFX shareholders will get equity in Leo via a pro rata entitlement offer and we note many brokers with LEO valuations of >\$1.5bn or more than current market capitalisation of FFX.

The uranium sector performed well during the month with the spot price hitting US\$60/lb leading to a rally in most uranium equities. Our holding in Lotus Resources Ltd ('LOT') was no exception and appreciated 37% for the month. It finished the month at \$0.40/sh, a record high current incarnation and a excellent return on our \$0.02/sh entry price.

Red Dirt Metals ('RDT') had a strong month up 30% as the Lithium sector shrugged off a poor February and roared ahead. With some very lofty market capitalisations on some of the more established names; RDT continues to screen reasonable value if exploration is successful is defining a modest sized resource. Our 'back of the envelope' estimates suggest a >15mt at 1.3 -1.5% LiO2, is certainly achievable from the mineralisation identified thus far.

Develop Global Ltd ('DVP') our largest portfolio holding was down 8% for the month with negative attribution of 1.5%. There was no specific company news and possibly some weakness post the \$50m placement and entitlements issue which was done at a premium to the underlying price. DVP was also added to the S&P All Ords effective from mid March. We are expecting an update on the Sulphur Springs drilling program shortly and an updated DFS in the  $3^{rd}$  Q CY'22.

Our graphite exposure Evolution Energy Ltd ('EV1') fell 10% for the month also on no news. We used this weakness to add to our position and remain confident it has all the ingredients to become a successful vertically integrated graphite producer. It remains very cheap in comparison to its peers.


Weakness in global life science companies continued to impact our position in PYC Therapeutics ('PYC') which was down a further 9% after falling 25% in the preceding month. It did announce it had successfully completed its pre Investigational New Drug engagement with US Food and Drug Administration in the RP11 program.

# Portfolio Performance

Top 3 Contributors		Bottom 3 Detractors		
Company	Sector	Company	Sector	
Firefinch Ltd	Lithium/Gold	Develop Global	Copper/Zinc	
Lotus Resources Ltd	Uranium	Evolution Energy	Graphite	
Red Dirt Metals Ltd	Lithium	PYC Therapeutics	Biotech	

#### <sup>1</sup> Returns after fees and taxes


### Growth of \$100,000 Since Inception




## **Top 5 Portfolio Holdings**

Company	Sector	Portfolio %
Develop Global Ltd	Copper	14.2
Orecorp Ltd	Gold	5.9
Centaurus Metals Ltd	Nickel	5.4
Capricorn Metals Ltd	Gold	5.1
Firefinch Limited	Lithium	4.0

#### Market Capitalisation Exposure



#### **Portfolio Composition**



<sup>&</sup>lt;sup>2</sup> The Benchmark being the average 90 day bill plus 2% (annually)

<sup>&</sup>lt;sup>3</sup> Inception date: October 2016